Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.43 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.43 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31348187 | 1.00 | SMYD3 (0.60) | SMYD3LMNAGAAPDE5AHDAC1 | |
| SCHEMBL19329581 | 0.87 | LMNA (0.57) | SMYD3LMNAGAAPDE5AALDH1A1 | |
| SCHEMBL19357202 | 0.87 | MAPT (0.60) | SMYD3LMNAGAAHDAC1HDAC2 | |
| SCHEMBL30204261 | 0.87 | LMNA (0.57) | SMYD3LMNAGAAPDE5AALDH1A1 | |
| SCHEMBL29913739 | 0.85 | SMYD3 (0.59) | SMYD3LMNAGAAHDAC1HDAC2 | |
| SCHEMBL3660693 | 0.85 | SMYD3 (0.59) | SMYD3LMNAGAAHDAC1HDAC2 | |
| SCHEMBL29630982 | 0.85 | LMNA (0.56) | SMYD3LMNAGAAMAPTHPGD | |
| SCHEMBL20894244 | 0.85 | LMNA (0.56) | SMYD3LMNAGAAMAPTHPGD | |
| SCHEMBL11319049 | 0.83 | SMYD3 (0.51) | SMYD3LMNAGAAHDAC1HDAC2 | |
| SCHEMBL24233407 | 0.83 | SMN1; SMN2 (0.60) | SMYD3LMNAGAAHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858919-B2 | HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858919-B2 | HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858919-B2 | HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220033388-A1 | HDAC1,2 Inhibitors | REGENACY PHARMACEUTICALS, LLC | 2022-02-03 | — | — | US | disclosed |
| US-20220033388-A1 | HDAC1,2 Inhibitors | REGENACY PHARMACEUTICALS, LLC | 2022-02-03 | — | — | US | disclosed |
| EP-3856174-A1 | HDAC1,2 INHIBITORS | Regenacy Pharmaceuticals, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020068950-A1 | HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC (US) | 2020-04-02 | — | — | WO | disclosed |
| CN-107072205-A | SMYD inhibitors | EPIZYME股份有限公司 | 2017-08-18 | — | — | CN | disclosed |
| WO-2016131789-A1 | BENZOPYRROLIDONE DERIVATIVES POSSESSING ANTIVIRAL AND ANTICANCER PROPERTIES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-08-25 | — | — | WO | disclosed |
| EP-3056202-A1 | BENZOPYRROLIDONE DERIVATIVES POSSESSING ANTIVIRAL AND ANTICANCER PROPERTIES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-08-17 | — | — | EP | disclosed |
| US-8354443-B2 | Cyclopropane indolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2509946-A1 | SPIRO INDOLE - CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011070039-A1 | SPIRO INDOLE - CYCLOPROPANE INDOLINONES USEFUL AS AMPK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| WO-2011069298-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | disclosed |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| WO-2009034029-A2 | 1-SUBSTITUTED 4-HETEROCYCLYLPIPERIDINES FOR USE AS CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-19 | — | — | WO | disclosed |
| US-6228868-B1 | ANTICARCINOGENIC AND ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-08 | — | — | US | disclosed |
| WO-2000006556-A1 | SUBSTITUTED OXAZOLINES AS ANTIPROLIFERATIVE AGENTS | ABBOTT LABORATORIES (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | GPR119, CPT1A, IRS1 | SMYD3 3616/4885LMNA 3395/4885GAA 2522/4885 |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | SMYD3 692/4885LMNA 2009/4885GAA 22/4885 |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | SMYD3 692/4885LMNA 2009/4885GAA 22/4885 |
| US-11858919-B2 | HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | SMYD3 1985/4885LMNA 2655/4885GAA 206/4885 |
| US-20220033388-A1 | HDAC1,2 Inhibitors | HDAC1, HDAC2, HDAC11 | SMYD3 1985/4885LMNA 2655/4885GAA 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.